Published

Company on brink takes psilocybin to trial for fragile X syndrome

No abstract is available for this record.

Open source BibTeX RIS

Bibliographic context

Journal: The Transmitter
Date: 2022-12-31
Source: OpenAlex
DOI: 10.53053/mkkk7368
PubMed: Unavailable

Authors

Peter Hess

Watch author

Topics and keywords

psilocybin General Other Psilocybin Psychoanalysis Psychology Psychiatry Psychotherapist Medicine Hallucinogen Psychedelics and Drug Studies Neuroethics Human Enhancement Biomedical Innovations

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

Company on brink takes psilocybin to trial for fragile X syndrome2022-12-31

Related papers

The psychedelic renaissance: psilocybin, a breakthrough for treatment resistant depression?Exploration of neuroscience · 2025-08-06 Esse quam Videre: Critical Reflections on the Use of Psilocybin as an Adjuvant in Psychedelic-Assisted PsychotherapyPolymatheia. · 2025-02-14